Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | PD173074 |
Trade Name | |
Synonyms | PD-173074|PD 173074 |
Drug Descriptions |
PD173074 is an ATP-competitive inhibitor of FGFR1, FGFR3, FGFR4, and KDR (VEGFR2), which may reduce proliferation and induce apoptosis in cancer cells (PMID: 9774334, PMID: 24126887, PMID: 14715624, PMID: 30544798). |
DrugClasses | FGFR1 Inhibitor 28 FGFR3 Inhibitor 21 FGFR4 Inhibitor 10 VEGFR2 Inhibitor 37 |
CAS Registry Number | 219580-11-7 |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ABT-737 + PD173074 | ABT-737 PD173074 | 3 | 0 |
Dasatinib + PD173074 | Dasatinib PD173074 | 1 | 0 |
Fulvestrant + Palbociclib + PD173074 | Fulvestrant PD173074 Palbociclib | 0 | 0 |
Fulvestrant + PD173074 | Fulvestrant PD173074 | 0 | 0 |
Gefitinib + PD173074 | Gefitinib PD173074 | 0 | 0 |
Palbociclib + PD173074 | PD173074 Palbociclib | 0 | 0 |
PD173074 | PD173074 | 32 | 0 |
PD173074 + Quizartinib | PD173074 Quizartinib | 0 | 0 |
PD173074 + Trabectedin | PD173074 Trabectedin | 1 | 0 |